Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
Health Trackers Supply Perception Into Efficiency Standing, Toxicities Amongst Sufferers With CRC
Using a fitness tracking device (Fitbit Charge ) as a prognostic tool was feasible and acceptable in a study evaluating 80 colorectal cancer (CRC)...
County Diet Menu – July 19-23 – The Stanly Information & Press
Nutritional menu of the district - 19.-23. July
...